The global pharmaceutical industry is experiencing surging demand for Sacubitril, the active neprilysin inhibitor used in combination with Valsartan to treat chronic heart failure with reduced ejection fraction (HFrEF). As the fixed‑dose combination Entresto (LCZ696) continues to generate blockbuster sales and generic competition rapidly expands, procurement professionals need a reliable, data‑driven overview of the international supply chain. This article provides a comprehensive guide to Sacubitril global buyers, verified importers, leading manufacturers, and best practices for pharmaceutical sourcing. All data is derived from customs‑recorded trade flows, regulatory filings, and industry‑validated intelligence, ensuring actionable insights for B2B decision‑makers. 1. Global Market Overview: Why Sacubitril Sourcing Matters The Sacubitril Valsartan Sodium tablets market…